AFG Venture Group Dispatches
Corporate advisory and consultancy in Australia, South East Asia and India.
Archive for Health and Life Sciences
CEDA report – ‘Healthcare: Reform or ration’
CEDA – the Committee for Economic Development of Australia – is a national, independent, member-based organisation providing thought leadership and policy perspectives on the economic and social issues affecting Australia. CEDA recently released its policy perspective entitled ‘Healthcare: Reform or ration’ available here: http://www.ceda.com.au/media/302619/healthcarefinal1.pdf The Executive Summary discusses increase in health expenditure linked to increased level of utilisation […]
Making A Difference
Ian Dixon Founder and CEO, Genscreen Group Every day I seek to use my own skills – and those around me – to make a tangible difference to the lives of others – and make some money when we are successful. My chosen vocation is the development of human therapeutics (and diagnostics) to solve serious […]
Cell Therapy Commercialisation
David James Director Life Sciences and Pharmaceutical, Invetech Introduction Cell therapies are being investigated for an ever increasing range of applications to treat infectious diseases such as AIDS, repair spinal cord injuries, repair cartilage, strengthen immune systems, and treat neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and epilepsy. Other potential applications include treating arteriosclerosis […]
Internet Cognitive Behaviour Therapy for Anxiety and Depression is a Disruptive Innovation
Gavin Andrews AO, MD Professor of Psychiatry, Clinical Research Unit for Anxiety and Depression, UNSW at St Vincent’s Hospital Each week I see 8 new patients referred to a specialist anxiety and depression clinic for cognitive behaviour therapy. On average, three are not suitable referrals, one will need face to face treatment which now will […]
2011 – Another Big Year for Australian Biotech
David Langsam Editor, Biotech Daily Australian biotechnology companies are on a dramatically upward trajectory, which – barring major global upheavals – shows no sign of abating. 2011 is going to be a very big year for biotech, primarily because most of the Biotech Daily Top 20 Index (BDI-20) companies have several major milestones during the […]